PURE Bioscience Appoints Dave Pfanzelter to Board of Directors

  PURE Bioscience Appoints Dave Pfanzelter to Board of Directors

Business Wire

SAN DIEGO -- February 13, 2013

PURE Bioscience, Inc. (NASDAQ: PURE), creator of the patented silver
dihydrogen citrate (SDC) antimicrobial, today announced that food industry
leader Dave Pfanzelter has been appointed to the Board of Directors. Mr.
Pfanzelter has been a member of PURE Bioscience’s Advisory Panel since July
2012. His appointment increases the number of PURE directors to six, four of
whom are considered independent, including Mr. Pfanzelter.

Michael L. Krall, President and CEO of PURE Bioscience, stated, “Since joining
our Advisory Panel last year, Dave has been instrumental in helping develop
our commercial initiatives into key market channels in food processing, food
manufacturing and food service. As a member of our Board of Directors, his
insight and relationships in the food industry will play an important role as
we refine and implement our sales and growth strategy.”

Dave Pfanzelter said, “This is an excellent opportunity to join the Board,
because I believe that PURE’s SDC-based technology provides a superior and
much-needed solution to the problem of foodborne illness. I look forward to
working with the other Directors and PURE’s management to position the Company
as a leader in food safety.”

Previously Mr. Pfanzelter was senior vice president, Kellogg Company,
president, Kellogg’s Specialty Channels and president, Kellogg Canada while
also serving as part of the Kellogg Executive Committee and Global Leadership
Team. Mr. Pfanzelter began his foodservice career in 1975 with Oscar Mayer
Foods Corporation serving in several key sales and marketing positions,
including director of marketing and national sales manager. In 1995, he was
appointed vice president, sales of Kraft Foodservice, representing the
combined manufactured brands of Oscar Mayer, General Foods and Kraft Foods. In
1998 Mr. Pfanzelter joined Keebler, serving as vice president and general
manager of the food service division prior to Keebler’s acquisition by Kellogg
in 2001.

Since 1998, Mr. Pfanzelter has been on the board of directors of Doctor’s
Associates, the parent company of Subway Restaurants, the nation’s largest
restaurant chain. In February 2012, Dave joined Wrigley Foods Advisory Board
of Directors. He also served on the Board of the International Food Service
Manufacturer’s Association as chairman and member of its executive committee.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. develops and markets technology-based bioscience
products that provide solutions to numerous global health challenges,
including Staph (MRSA) and Carbapenem-resistant Enterobacteriaceae
(CRE)/NDM-1+. PURE’s proprietary high efficacy/low toxicity bioscience
technologies, including its silver dihydrogen citrate-based antimicrobials,
represent innovative advances in diverse markets and lead today’s global trend
toward industry and consumer use of “green” products while providing
competitive advantages in efficacy and safety. Patented SDC is an
electrolytically generated source of stabilized ionic silver, which formulates
well with other compounds. As a platform technology, SDC is distinguished from
competitors in the marketplace because of its superior efficacy, reduced
toxicity and the inability of bacteria to form a resistance to it. PURE is
headquartered in El Cajon, California (San Diego metropolitan area).
Additional information on PURE is available at www.purebio.com.

This press release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate," "project,”
"expect" or similar expressions. These statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements inherently involve risks and uncertainties
that could cause actual results to differ materially from the forward-looking
statements. Factors that would cause or contribute to such differences
include, but are not limited to, the Company’s cash position and liquidity
requirements, the Company’s failure to implement or otherwise achieve the
benefits of its strategic initiatives, acceptance of the Company's current and
future products and services in the marketplace, the ability of the Company to
develop effective new products and receive regulatory approvals of such
products, competitive factors, dependence upon third-party vendors, and other
risks detailed in the Company's periodic report filings with the Securities
and Exchange Commission. By making these forward-looking statements, the
Company undertakes no obligation to update these statements for revisions or
changes after the date of this release.

Contact:

PURE Bioscience Investor Contact:
Don Markley, Senior Vice President, LHA
310-691-7100
dmarkley@lhai.com